Post-therapy status of paracoccidioidomycosis treated with ketoconazole.
Twenty-four paracoccidioidomycosis patients who completed a course of therapy with ketoconazole were followed for 12 months after treatment, and 10 of these patients were followed for 24 months. Only two of these patients relapsed; the remaining continued in remission. There were no fatalities. Immunologic tests showed decreased antibody activity and increased skin test reactivity to paracoccidioidin in comparison with the results obtained at the end of therapy. These findings indicate that ketoconazole therapy has improved the prognosis of patients with paracoccidioidomycosis.
D000908:Antibodies, Fungal / Q000032:analysis; D000935:Antifungal Agents / Q000627:therapeutic use*; D005500:Follow-Up Studies; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use*; D007654:Ketoconazole; D008297:Male; D010229:Paracoccidioidomycosis / Q000188:drug therapy* / Q000276:immunology / Q000401:mortality; D010879:Piperazines / Q000627:therapeutic use*; D011379:Prognosis; D012008:Recurrence
D000908:Antibodies, Fungal; D000935:Antifungal Agents; D007093:Imidazoles; D010879:Piperazines; D007654:Ketoconazole